Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Having founded in 1994, the company conducted various preclinical development programs, including the BEXXAR® therapy and the MELACINE® vaccine. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are powered by Corixa™ technology with the goal of making its potential products available to patients around the world. Corixa was acquired by GlaxoSmithKline on 12 July 2005, and GSK had formerly made use of the Corixa's MPL adjuvant in some of their vaccines. The company ceased operations in March 2006.

Eyegene, Inc. engages in the research and development of pharmaceutical products. Its products include curing technologies and vaccines for diabetic retinopathy, decubitus ulcer, cervical cancer, and adjuvant immunotherapy. The company was founded on June 23, 2000 and is headquartered in Seoul, South Korea.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Infectious Disease Research Institute operates as a innovative science to research and development company. It offers pipeline, adjuvants, vaccines, diagnostics and drugs products. The firm also provides manufacturing, analytical methods, stability studies, process and contact services. The company was founded by Steven G. Reed in 1993 and is headquartered in Seattle, WA.

Institut Jean Paoli & Irene Calmettes is a non-profit organization engaging in fighting cancer. The company is headquartered in Marseille, France.

Chengdu Yongan Pharmaceutical Co., Ltd., established on 1992-12-02, Business scope includes research and development of health care products,biochemical agent;Drug development and production(Solution(external use),film,hard capsule,tablet,Granules);Development and production of medical devices(only6840In vitro diagnostic reagents);potatoes,Planting of vegetables;mannose oligosaccharide,Production and sales of konjac products;engage in technology transfer,technical consulting;Agricultural Science and Technology,research and develop,technical consulting;Import and export,Technology Import and Export;Machinery and Equipment Leasing;Realtor;Research and Development of Disinfectants,Production,Sales;Development and production of biological products,Sales(human stem cells,Except for the development and application of genetic diagnosis and treatment technology);Production of Feed Additives,Sales.(Except those involving the implementation of special access management measures stipulated by the state)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Pace Diagnostics, Inc. is a biotechnology company focuses on the research, development, licensing, manufacturing, and marketing of diagnostics. The company was founded by Hiep-Hoa Anthony T. Nguyen, Lorne T. Mattner, Sanjay Jayachandran, and Marianne M.T. Nguyen and is headquartered in Monrovia, CA.

Virginia Tech Intellectual Properties, Inc. handles, protects and licenses technologies developed by the faculty, staff and students. It facilitates the licensing of technology to companies, encourages new faculty startup ventures, works with publishers and distributors of software, and supports the transfer of research and knowledge to other universities, research institutes and companies. The company was founded in 1985 and is headquartered in Blacksburg, VA.

Guangzhou Diao Medical Technology Co., Ltd., established on 2014-07-21, Business scope includes biotechnology consulting,communication service;Operation of non-licensed medical devices;Import and export(Excluding franchised products);Biotechnology Transfer Services;Biotechnology Development Services;car retail;Retailing of office equipment consumables;Wholesale of office equipment consumables;software service;software retail;Instrument wholesale;Instrument Repair;Sales of Biological Products(Does not include licensed operations);Sales of biological diagnostic reagents and kits(Does not include license approval items);Manufacturing of experimental analysis instruments;Commodity wholesale trade(Except for licensed and approved products);Technology Import and Export;Commodity retail trade(Except for licensed and approved products);Manufacturing of instrumentation and other general instruments for supply;Manufacturing of electronic measuring instruments;Optical Instrument Manufacturing;Components for general and special purpose instrumentation,Device manufacturing;Medical supplies and equipment retail(Does not contain drugs and medical devices);Auto Parts Retail;motorcycle retail;computer retail;Electronics retail;General machinery and equipment retail;Machinery Parts Retail;Chemical Product Retail(Excluding hazardous chemicals);Food Science and Technology Research Services;medical diagnosis,Monitoring and treatment equipment manufacturing;Licensed medical device business;

Green Cross continues to build on a long legacy of providing life-saving and life-sustaining specialty therapeutics. Their bioscience division began its business in 1971 as producing plasma-derived biotherapies for the first time in Korea. For more than 40 years, they have specialized in providing biotherapeutics to improve the quality of life for people with rare and serious diseases worldwide. Their vaccine business develops and produces paediatric and adult vaccine against a broad range of infectious diseases, from world’s 3rd hepatitis B vaccine to quadrivalent influenza vaccine. With their mission to improve health and well-being of people around the world, they have gone down a path that nobody wishes to explore. Their extensive research and development of innovative medicines that support treatment and prevention as well as cures for diseases in a wide range of therapeutic areas demonstrate their ongoing commitment to all people who rely on their products.

Shanghai Rongsheng Biotech Co., Ltd. principally engages in the research, development, production, and sale of vaccines and in vitro diagnostic reagents. Its products include vaccines, immunodiagnosis reagents, and biochemical diagnosis reagents. The company was founded by Shao Rong Zhu in 1988 and is headquartered in Shanghai, China.

Beijing Xiangrui Biological Products Co., Ltd., established on 2000-03-24, Business scope includes production,Sales of small volume injections[vaccine(ACmeningococcal conjugate vaccine),In Vivo Diagnostic Reagents(Tuberculin pure protein derivative,BCG Pure Protein Derivatives)];Sales of Class III Medical Devices;Production of Class III medical devices(Production of in vitro diagnostic reagents);biotechnology development,consult,transfer;Import and export,Technology Import and Export,Agent import and export;SalesI,IIclass of medical devices.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Production of Class III medical devices(Production of in vitro diagnostic reagents)and items that are legally subject to approval,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

TB Healthcare is a provider of tuberculosis prevention, diagnosis, and treatment services. They provide comprehensive tuberculosis solutions, including clinical in vitro diagnostic reagents, bacterial ultrasonic dispersive counters, vacuum pumps, and proteome products.

Theravectys is a development-stage biotechnology company with a novel vaccine platform that can be applied to the treatment and prevention of a broad range of infectious diseases, cancers, and other diseases and conditions. Their first clinical studies will be in HIV/AIDS, using their lead product, a therapeutic vaccine, which has shown promising efficacy and safety in non-human primates.